Ezetimibe + simvastatin

PBAC's latest decision on Ezetimibe + simvastatin: Noted (2014). Considered for Adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate; and for homozygous familial hypercholesterolaemia.

Eligible population

Patients with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia, or homozygous familial hypercholesterolaemia, currently controlled on Vytorin.

Therapy area

Cardiovascular

Line of therapy

Any

Evidence base

Single-arm

Primary endpoint

Other

Pivotal trial size

16,594 patients

Key trials

Vytorin Compliance Study IV

Comparator

concomitant ezetimibe and statin therapy, atorvastatin + ezetimibe co-pack, rosuvastatin + ezetimibe combination

Economic model

Not modelled

ICER note

This was a compliance submission under subsection 101(4AC) of the Act, not an economic evaluation. No ICER calculated.

Similar precedents

• Ezetimibe with simvastatin
  similarity 0.96
• Ezetimibe and atorvastatin
  similarity 0.82
• Ezetimibe + atorvastatin
  similarity 0.81
• Ezetimibe and rosuvastatin
  similarity 0.79
• Ezetimibe + rosuvastatin
  similarity 0.78
• Inclisiran
  similarity 0.68